The second China clinical research quality management (GCP) and innovative drug R & D conference was successfully held

Source: China pharmaceutical innovation promotion association on June 10-11, 2017, the second China clinical research quality management (GCP) and innovative drug research and development conference jointly sponsored by China Pharmaceutical Innovation Promotion Association (hereinafter referred to as "China pharmaceutical promotion association"), China Cardiovascular Health Alliance and China antithrombotic drug treatment alliance was held in Yantai, Shandong Province Guests present at the conference include: Wang Lifeng, director of the Department of drug and cosmetics registration, State Food and drug administration, Liu Pei, inspector of the legal department, State Food and drug administration, Zhang Yongxia, mayor of Yantai City, song Ruilin, executive chairman of China Association for the promotion of drugs, Ma Yuenan, director of Shandong food and drug administration, Li Jianming, deputy director of the national drug audit and inspection center, and National Health Bureau Xie Dongfang, deputy director of the Department of science and education of the livelihood Health Committee; GE Junbo, chairman of China Cardiovascular Health Alliance and director of Cardiology Department of Zhongshan Hospital Affiliated to Fudan University; Wang Yongjun, executive vice president of Beijing Tiantan Hospital Affiliated to Capital Medical University, Shi Yuankai, vice president of Cancer Hospital of Chinese Academy of Medical Sciences, Huo Yong, vice chairman of China cardiovascular health alliance, director of Cardiology and heart center of Peking University First Hospital, Cui Yimin, director of China antithrombotic drug treatment alliance, clinical trial center of Peking University First Hospital, Li Wenbin, director of brain glioma Department of Beijing Century Altar Hospital Affiliated to Capital Medical University, etc Many experts in the fields of basic research of medicine and clinical research institutions There are also medical experts from local innovative enterprises and multinational pharmaceutical enterprises, and a total of 300 staff members from clinical research institutes and enterprises attended the meeting Wang Lifeng, director general of the Department of drug and cosmetic registration of the State Food and Drug Administration (CFDA), aims to deepen the reform of drug review and approval mechanism and establish a policy system to encourage pharmaceutical innovation, aiming at improving the ability of drug technology review, accelerating the review and approval of new medical devices on the market, promoting the balanced development of innovation and imitation, and implementing the full life cycle management and purification of drugs The policy system of drug R & D environment was explained comprehensively Report by Wang Lifeng, director of CFDA drug and cosmetic registration management department In his speech, song Ruilin, executive chairman of China pharmaceutical promotion association, pointed out that China is in a period of great change in pharmaceutical innovation Recently, the relevant departments of the state have intensively issued a series of policies to encourage pharmaceutical innovation We should take this opportunity, firmly seize the opportunity, take the lead, take the initiative to meet the challenges, and dare to explore and establish pharmaceutical patent links and patent period compensation suitable for China's national conditions To create a global vision and perfect pharmaceutical innovation policy environment Song Ruilin, executive chairman of China Association for the promotion of drugs, addressed the meeting, and Mayor Zhang Yongxia of Yantai City, looked forward to the success of the meeting to provide more opportunities for the innovative development of medicine in Yantai city Zhang Yongxia, mayor of Yantai City, delivered a speech Ge Junbo, chairman of China Cardiovascular Health Alliance and director of Cardiology Department of Zhongshan Hospital Affiliated to Fudan University also delivered a speech at the conference Speech by academician Ge Junbo At the conference, a number of experts from drug audit and inspection institutions, medical institutions and pharmaceutical enterprises, centering on the higher requirements of the reform policies proposed by CFDA, such as accelerating the review and approval of new drugs on the market, reforming clinical trial management, etc., set up a clinical multi center drug clinical trial research system and quality and data management system that meet international standards as soon as possible to promote the clinical research of new drugs in China The research level and research efficiency have been improved rapidly, and domestic innovative drug research and development has been promoted to be in line with international standards From different perspectives in various professional fields, the conference has presented a number of brilliant thematic reports, and conducted in-depth discussion and interaction with representatives Expert report, expert guests and representatives The successful holding of the conference is of great significance to promote the scientific and standardized development of clinical trials of drugs in China, accelerate the listing of drugs urgently needed in clinical practice and for the treatment of major diseases in China, achieve the breakthrough of the internationalization of innovative drugs in China, and improve the innovation and international competitiveness of Chinese pharmaceutical industry and clinical research institutions! Conference site